---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-008503"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2022-03-31T23:59:59+00:00"
generated_at: "2026-06-26T11:33:30.934914+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Interpace 2021 rev $41.3M (+28%), net loss improves to -$14.9M; CMS reversal on thyroid tests

## Summary
- Full year 2021 net revenue $41.3M, up 28% YoY; Q4 revenue $10.9M, up 13% YoY.
- Net loss improved to $(14.9)M from $(26.5)M; Adjusted EBITDA $(5.1)M vs $(15.4)M.
- Cash collections $43.1M, up 31%, outpacing revenue; DSO decreased 40% to 54 days.
- CMS retroactively reversed Jan 2022 billing policy for ThyGeNEXT/ThyraMIR; cash collections may be delayed.
- Appointed Dr. Vijay Aggarwal to board, replacing Eric B. Lev, effective Feb 1, 2022.

## SEC filing metadata
- accession: 0001493152-22-008503
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2022-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315222008503/0001493152-22-008503-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315222008503/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-008503
- JSON: https://secwatch.observer/filing/0001493152-22-008503.json
- Plain text: https://secwatch.observer/filing/0001493152-22-008503.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.